Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Instagram
  • Listen to CMAJ podcasts
Letters

List of essential medicines for Canada

Ronald D. Barr
CMAJ May 15, 2017 189 (19) E703; DOI: https://doi.org/10.1503/cmaj.732971
Ronald D. Barr
Founding Chair, Working Group on Essential Medicines, International Society of Paediatric Oncology, and Department of Pediatrics, McMaster University, Hamilton, Ont.
MBChB MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

The articles by Morgan and colleagues in CMAJ,1 and Taglione and colleagues in CMAJ Open2 are useful prompts for resolving the continuing conjoint debates about a national list of essential medicines and a national pharmacare program in Canada. Unfortunately, their contributions are limited by the self-imposed restrictions to the prescribing practices of family physicians. Almost completely excluded from consideration are the drugs required to treat cancer in children, adolescents and young adults.

Cancer is the most common cause of disease-related death in this age group (0 to 29 years) in Canada beyond the first year of life,3 yet five-year survival rates exceed 80%,4 and the potential years of life saved are second only to those among women with breast cancer. Most drugs that have contributed to this success have been available for decades and are inexpensive. From the list of these drugs (n = 30) proposed by an expert group5 and subject to study by the World Health Organization (WHO),6 only four are included in the list proposed by Morgan and colleagues1 — methylprednisolone, prednisone, tretinoin and methotrexate. The steroids and methotrexate are almost certainly not prescribed by family physicians for lymphoblastic leukemias and lymphomas, whereas their prescriptions for tretinoin mostly will be as topical medications for nonmalignant skin diseases rather than for acute promyelocytic leukemia, the only cancer indication.

Moreover, the work involved in 2014 to propose the addition of nine drugs to the WHO Essential Medicines List for the treatment of cancer in children was rewarded when the WHO Expert Committee approved all nine drugs at its biennial meeting in 2015.7 Only one of these medications (tretinoin) is included in the proposed essential medicines list for Canada.

Although the development of a national essential medicines list is a laudable objective, it must be recognized that this will be a dynamic entity that is subject to additions and deletions. Much work remains to be done.

Footnotes

  • Competing interests: None declared.

References

  1. ↵
    1. Morgan SG,
    2. Li W,
    3. Yau B,
    4. et al
    . Estimated effects of adding universal public coverage of an essential medicines list to existing public drug plans in Canada. CMAJ 2017;189:E295–302.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Taglione MS,
    2. Ahmad H,
    3. Slater M,
    4. et al
    . Development of a preliminary essential medicines list for Canada. CMAJ Open 2017;5:E137–43.
    OpenUrl
  3. ↵
    Canadian cancer statistics 2008. Toronto: Canadian Cancer Society/National Cancer Institute of Canada; 2008:60–77.
  4. ↵
    1. De P,
    2. Ellison LF,
    3. Barr RD,
    4. et al
    . Canadian adolescents and young adults with cancer: opportunity to improve coordination and level of care. CMAJ 2011;183:E187–94.
    OpenUrlFREE Full Text
  5. ↵
    1. Mehta PS,
    2. Wiernikowski JT,
    3. Petrilli JAS,
    4. et al
    . Essential medicines for pediatric oncology in developing countries. Pediatr Blood Cancer 2013;60:889–91.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Barr R,
    2. Robertson J
    . Access to cytotoxic medicines by children with cancer: a focus on low and middle income countries. Pediatr Blood Cancer 2016;63:287–91.
    OpenUrl
  7. ↵
    1. Shulman LN,
    2. Wagner CM,
    3. Barr R,
    4. et al
    . Proposing essential medicines to treat cancer: methodologies, processes and outcomes. J Clin Oncol 2016;34:69–75.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 189 (19)
CMAJ
Vol. 189, Issue 19
15 May 2017
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
List of essential medicines for Canada
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
List of essential medicines for Canada
Ronald D. Barr
CMAJ May 2017, 189 (19) E703; DOI: 10.1503/cmaj.732971

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
List of essential medicines for Canada
Ronald D. Barr
CMAJ May 2017, 189 (19) E703; DOI: 10.1503/cmaj.732971
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Footnotes
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • Estimated effects of adding universal public coverage of an essential medicines list to existing public drug plans in Canada
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • The 5 Ps need an update: toward a comprehensive sexual history
  • Don’t ignore perimenopause
  • Hospital-at-home programs in Canada: challenges and pitfalls
Show more Letters

Similar Articles

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: [email protected]

CMA Civility, Accessibility, Privacy

 

Powered by HighWire